.

Pharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,551,957

« Back to Dashboard

Which drugs does patent 8,551,957 protect, and when does it expire?

Patent 8,551,957 protects JARDIANCE and GLYXAMBI and is included in two NDAs.

This patent has thirty-four patent family members in twenty-four countries.

Summary for Patent: 8,551,957

Title:Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Inventor(s): Dugi; Klaus (Dresden, DE), Mark; Michael (Biberach, DE), Thomas; Leo (Biberach, DE), Himmelsbach; Frank (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim Am Rhein, DE)
Application Number:12/673,327
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo8,551,957► Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-002Aug 1, 2014RXYesYes8,551,957► Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer Ingelheim
GLYXAMBI
empagliflozin; linagliptin
TABLET;ORAL206073-001Jan 30, 2015RXYesNo8,551,957► SubscribeY METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer Ingelheim
GLYXAMBI
empagliflozin; linagliptin
TABLET;ORAL206073-002Jan 30, 2015RXYesYes8,551,957► SubscribeY METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,551,957

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07114459Aug 16, 2007
PCT Information
PCT FiledAugust 15, 2008PCT Application Number:PCT/EP2008/060736
PCT Publication Date:February 19, 2009PCT Publication Number: WO2009/022007

International Patent Family for Patent: 8,551,957

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand583242► Subscribe
Malaysia152037► Subscribe
Mexico2010001696► Subscribe
Morocco31612► Subscribe
South Korea101491554► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc